Table 4. Correlation between clinico-pathological factors and positive immunostaining of all proteins analysed.
|
Positive IHC staining (%) (n positive/n total)
|
||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
No. of cases
|
MYCa
|
BARK1a
|
PP1αa
|
FASNa
|
NM23-H1b
|
PP2Aa,b
|
||||||||
| Clinico-pathological factor | Tumour (n=131) | BPH (n=126) | Tumour | BPH | Tumour | BPH | Tumour | BPH | Tumour | BPH | Tumour | BPH | Tumour | BPH |
| Gleason score | ||||||||||||||
| 5–6 | 45 | 59 | 74% | 80% | 100% | 100% | 63% | 51% | 54% | 16% | 59% | 55% | 60% | 60% |
| 7 | 31 | 24 | 54% | 74% | 93% | 87% | 64% | 55% | 59% | 18% | 62% | 71% | 60% | 61% |
| 8–9 | 45 | 27 | 28% | 68% | 85% | 78% | 84% | 68% | 57% | 14% | 59% | 76% | 43% | 50% |
| 121c | 110c | |||||||||||||
| P-value | <0.001 | 0.501 | 0.040 | 0.003 | 0.074d | 0.385 | 0.910 | 0.918 | 0.974 | 0.134 | 0.280 | 0.686 | ||
| Adjusted P-valuee | 0.002 | 1.000 | 0.240 | 0.024 | 0.052 | 1.000 | 1.000 | 1.000 | 1.000 | 0.804 | 1.000 | 1.000 | ||
| pT-stage | ||||||||||||||
| pT2 | 60 | 80 | 73% | 79% | 96% | 92% | 66% | 58% | 59% | 14% | 61% | 60% | 55% | 54% |
| pT3-pT4 | 49 | 33 | 36% | 70% | 93% | 87% | 73% | 48% | 63% | 19% | 60% | 70% | 55% | 53% |
| 109c | 113c | |||||||||||||
| P-value | <0.001 | 0.324 | 0.657 | 0.477 | 0.515 | 0.392 | 0.832 | 0.556 | 1.000 | 0.375 | 1.000 | 1.000 | ||
| Adjusted P-valuee | 0.006 | 1.000 | 1.000 | 1.000 | 1.000 | 1.000 | 1.000 | 1.000 | 1.000 | 1.000 | 1.000 | 1.000 | ||
BARK1=β-adrenergic receptor kinase 1; FASN=Fatty acid synthase; PP2A=protein phosphatases.
a
Cytoplasmic immunostaining.
b
Nuclear immunostaining.
c
No. of samples for which the respective clinico-pathological data were available. Not all BPH samples correspond to the same patients as the tumour samples.
d
For Gleason scores 5–7 vs 8–9, p=0.001.
e
P-values of Gleason score and pT-stage were corrected for multiple testing using Bonferroni-Holm for all proteins in this study.